Sunday, February 25, 2024
BestWooCommerceThemeBuilttoBoostSales-728x90

Ann Robinson’s research reviews—15 February 2024



Resmetirom for non-alcoholic steatohepatitisThe global incidence of non-alcoholic fatty liver disease is estimated to be one in 20. About a fifth of cases will cause liver cell inflammation and damage known as non-alcoholic steatohepatitis (NASH). As NASH progresses to severe fibrosis and on to cirrhosis, the risk of death from liver disease increases. Lifestyle changes help early stage NASH, but there’s no approved drug treatment as yet. This phase 3 trial is encouraging. Among 966 patients with NASH, resmetirom (80 mg and 100 mg doses)—an oral, liver-directed, thyroid hormone receptor agonist that reduces fibrosis—was more effective than placebo in resolution of NASH with no worsening of fibrosis (26% v 30% v 10%) and improving liver fibrosis (24% v 26% v 14%) over one year. Lipid profiles improved too, which is helpful as most of these patients with NASH also had diabetes and are at increased risk of cardiovascular disease. N…



Source link

Related Articles

Leave a Reply

[td_block_social_counter facebook="beingmedicos1" twitter="being_medicos" youtube="beingmedicosgroup" style="style8 td-social-boxed td-social-font-icons" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjM4IiwiZGlzcGxheSI6IiJ9LCJwb3J0cmFpdCI6eyJtYXJnaW4tYm90dG9tIjoiMzAiLCJkaXNwbGF5IjoiIn0sInBvcnRyYWl0X21heF93aWR0aCI6MTAxOCwicG9ydHJhaXRfbWluX3dpZHRoIjo3Njh9" custom_title="Stay Connected" block_template_id="td_block_template_8" f_header_font_family="712" f_header_font_transform="uppercase" f_header_font_weight="500" f_header_font_size="17" border_color="#dd3333"]
- Advertisement -spot_img

Latest Articles